2016
Phase I study of pemetrexed with sorafenib in advanced solid tumors
Poklepovic A, Gordon S, Shafer DA, Roberts JD, Bose P, Geyer CE, McGuire WP, Tombes MB, Shrader E, Strickler K, Quigley M, Wan W, Kmieciak M, Massey HD, Booth L, Moran RG, Dent P. Phase I study of pemetrexed with sorafenib in advanced solid tumors. Oncotarget 2016, 7: 42625-42638. PMID: 27213589, PMCID: PMC5173162, DOI: 10.18632/oncotarget.9434.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCohort StudiesFemaleHumansInflammationMaleMaximum Tolerated DoseMiddle AgedNeoplasmsNiacinamidePemetrexedPhenylurea CompoundsPTEN PhosphohydrolaseSorafenibTreatment OutcomeTriple Negative Breast NeoplasmsConceptsAdvanced solid tumorsDay 1Solid tumorsOral sorafenibDose scheduleBreast cancerTriple-negative breast cancerDose-escalation schemaPhase II dosePhase I trialSorafenib dosingSorafenib therapyStable diseaseCohort BComplete responseI trialPartial responseTolerable combinationRadiographic assessmentCumulative toxicityCombination treatmentPatientsSorafenibPhase IAntitumor activity
1999
Comparison of cytotoxicity and cellular accumulation of polynuclear platinum complexes in L1210 murine leukemia cell lines
Roberts J, Peroutka J, Beggiolin G, Manzotti C, Piazzoni L, Farrell N. Comparison of cytotoxicity and cellular accumulation of polynuclear platinum complexes in L1210 murine leukemia cell lines. Journal Of Inorganic Biochemistry 1999, 77: 47-50. PMID: 10626353, DOI: 10.1016/s0162-0134(99)00137-3.Peer-Reviewed Original ResearchConceptsPolynuclear platinum complexesPlatinum complexesDiamine linkerL1210 cell lineDinuclear platinum complexesTrinuclear platinum complexL1210 murine leukemia cell lineL1210/DDPDinuclear complexesAnticancer profileChemical featuresCytotoxicity profileCellular uptakeBBR3464LinkerMurine leukemia cell lineComplexesTransCharge contributesClinical agentsCytotoxicityUptake pathwayCellular accumulationAntitumor activityPlatinumChemistry and Biology of Multifunctional DNA Binding Agents
Farrell N, Qu Y, Roberts J. Chemistry and Biology of Multifunctional DNA Binding Agents. Topics In Biological Inorganic Chemistry 1999, 99-115. DOI: 10.1007/978-3-662-03815-4_4.Peer-Reviewed Original Research
1991
Shikimic acid complexes of platinum. Preparation, reactivity, and antitumor activity of (R,R-1,2-diaminocyclohexane) bis(shikimato)platinum(II). Evidence for a novel rearrangement involving platinum—carbon bond formation
Farrell N, Roberts J, Hacker M, Farrell N, Roberts J, Hacker M. Shikimic acid complexes of platinum. Preparation, reactivity, and antitumor activity of (R,R-1,2-diaminocyclohexane) bis(shikimato)platinum(II). Evidence for a novel rearrangement involving platinum—carbon bond formation. Journal Of Inorganic Biochemistry 1991, 42: 237-246. PMID: 1880505, DOI: 10.1016/0162-0134(91)84038-b.Peer-Reviewed Original ResearchConceptsHigh-performance liquid chromatographyCarboxylate oxygenVinylic carbonBond formationAqueous solutionPerformance liquid chromatographyAcid complexesL1210 cell lineLiquid chromatographyHydrolysis productsComplexesComplex IIMajor hydrolysis productsL1210 leukemiaNovel rearrangementMoietyAntitumor activityPlatinumChromatographyReactivityOxygenPreparationCarbonComplex typeFormation
1987
Phase I trial of tiazofurin administered by i.v. bolus daily for 5 days, with pharmacokinetic evaluation.
Roberts JD, Stewart JA, McCormack JJ, Krakoff IR, Culham CA, Hartshorn JN, Newman RA, Haugh LD, Young JA. Phase I trial of tiazofurin administered by i.v. bolus daily for 5 days, with pharmacokinetic evaluation. Journal Of The National Cancer Institute 1987, 71: 141-9. PMID: 3802111.Peer-Reviewed Original ResearchConceptsTreatment interruptionTransient toxic effectsM2/dayTreatment coursePhase I clinical trialToxic effectsAntitumor activityPhase II trialPhase I trialBolus IV infusionFrequent treatment interruptionsSerum biochemical abnormalitiesSystemic toxic effectsCoadministration of allopurinolMurine tumor modelsUric acid productionLow dose levelsSignificant antitumor activityBolus dailyInjury manifestTransient pericarditisII trialSerum hemoglobinI trialIV infusion